Abstract
Background Countries have adopted disparate policies in tackling the COVID-19 coronavirus pandemic. For example, China closed down large areas almost completely to increase social distance; South Korea started a vigorous campaign to suppress the virus by testing patients with respiratory symptoms and tracing and isolating all their contacts; and many European countries try to slow down the spread of the virus with varying degrees of shutdowns. There is clearly a need for a model that can realistically simulate different policy actions and their impacts on the disease and health care capacity in a country or region. Specifically, there is a need to identify destructive policies, i.e. policies that are, based on scientific knowledge, worse than an alternative and that should not be implemented.
Methods We developed an agent-based model (REINA) using Python and accelerated it by the Cython optimising static compiler. It follows a population in time at individual level at different stages of the disease and estimates the number of patients in hospitals and in intensive care. It estimates death rates and counts based on the treatment available at each time point. Any number of interventions can be added on the timeline from a selection including e.g. physical isolation, testing and tracing, and controlling the amount of cases entering the area. The model has open source code and runs online.
Results The model uses the demographics of the Helsinki University Hospital region (1.6 million inhabitants). Two main scenarios were tested with several variants. The first, a mitigation strategy, aims to slow down the spread of the epidemic to maintain the hospital capacity by implementing mobility restrictions. The other, a suppression strategy, consists of the same mobility restrictions but also aggressive testing, tracing, and isolating all coronavirus positive patients and their contacts. Both take as their starting point the actual situation as of 2020-04-06. The default mitigation scenario with variable 30–40% mobility reduction appears able to delay the peak of the epidemic (as intended) but not to suppress the disease. In the suppression strategy, active testing and tracing of patients with symptoms and their contacts is implemented in addition to 20–25% mobility reduction. This results in a reduction during the first year of the cumulative number infected individuals from 820 000 to 80 000 and the number of deaths from 6000 to only 640, when compared with the mitigation strategy.
Discussion The agent-based model (REINA) can be used to simulate epidemic outcomes of various types of policy actions on a timeline. Our results lend support to the strategy of combining comprehensive testing, contact tracing and targeted isolation measures with social isolation measures. While latter are important in the early stages to prevent explosive growth, the mitigation strategy aiming to slow down the epidemic mainly via social isolation appears to be a destructive policy, i.e. a policy that has, based on scientific knowledge, better alternatives. The open-source nature of the model facilitates rapid further development. The flexibility of the modelling logic supports the future implementation of several already identified refinements in terms of more realistic population model and new types of more specific policy interventions. Improving estimates of epidemic parameters will make it possible to improve modelling accuracy further.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data and code used is available at Github.
